Beacon Biotechnology's Point of Care Type I Diabetes Screen

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$329,529.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK088490-01
Agency Tracking Number:
DK088490
Solicitation Year:
n/a
Solicitation Topic Code:
NIDDK
Solicitation Number:
n/a
Small Business Information
BEACON BIOTECHNOLOGY, LLC
BEACON BIOTECHNOLOGY, LLC, 12635 E. MONTVIEW BLVD., AURORA, CO, 80045
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
788151343
Principal Investigator:
CHRISTINA ROARK
() -
CROARK@BEACONBIOTECHNOLOGY.COM
Business Contact:
CHRISTINA ROARK
() -
llansing@beaconbiotechnology.com
Research Institution:
n/a
Abstract
* * Description of team not provided in the application aside from CVs thus making it difficult to assess quality. 3. Innovation: Strengths * Development of inexpensive, simple, disposable, point-of-care screening method attractive. * A ntigen-modified detector is unique. * Solid IP concerning bioluminescent molecules attached to the surface of a detector. Weaknesses * Clear description why ELISA has not proven successful for diabetes-related autoantibody testing lacking. * Pr oposal ignores other bioluminescence immunoassay products on the market. * What is envisioned cost per device? Instrument development not a part of the proposal. 4. Approach: Strengths * Detailed description of protein preparation (e.g., p reparation of biotinylated proteins, etc.) and use methodology comparing two methods for quantifying the relevant antibodies. * Alternative approaches proposed to counter potential pitfalls and if sensitivity or selectivity criteria are not met (i.e., e quivalent to current FDA approved methods). Weaknesses * Research and design merely compares two techniques that employ the BrightSPOT platform. Instrumentation neither described nor made clear if already complete. * Preliminary data based predomi nately on HIV application in pooled plasma. Where blood is used, it is first diluted. How this influences speed, limit of detection and sensitivity not clear. * Stability/shelf-life of immobilized antigen not addressed. 5. Environment: Strengt hs * Company seems to have adequate space, equipment, and resources. * Team will also take advantage of resources at the University of Colorado-Denver. Weaknesses * None Protections for Human Subjects: Not Applicable (No Human Subjects) Vertebrate Animals: Not Applicable (No Vertebrate Animals) Biohazards: Acceptable Budget and Period of Support: Recommended budget modifications or possible overlap identified: * No real evidence of need for additional 6 months (12 totals) of funding. * Budget too high for proposed work. Salary for individuals conducting work unrelated to proposal requested (e.g., FDA consultant, software development, etc.) but not warranted. Resource Sharing Plans: Not Applicabl e (No Relevant Resources)

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government